Claims for Patent: 6,509,004

Summary for Patent: 6,509,004

Title:	Process for preparing contrast agents
Abstract:	The invention provides a process for the preparation of a pharmaceutical composition comprising an aqueous dispersion of gas-containing vesicles the membranes whereof comprise an amphiphilic membrane-forming material, said process comprising: (i) generating a liquid dispersion of gas-containing vesicles from a mixture comprising an amphiphilic membrane forming material; (ii) lyophilizing a liquid dispersion of said gas-containing vesicles; (iii) reconstituting the lyophilized product of step (ii) with a sterile aqueous liquid to produce an aqueous dispersion of gas-containing vesicles; and (iv) treating the aqueous dispersion product of step (iii) or the lyophilized product of step (ii) to produce a substantially aggregate-free sterile aqueous dispersion of gas-containing vesicles.
Inventor(s):	Henriksen; Ingrid (Oslo, NO), Kasparkova; Vera (Slependen, NO), Andersen; Arnfinn (Oslo, NO), Fahlvik; Anne Kjersti (Oslo, NO), Odegardstuen; Liv Ingrid (Leirsund, NO)
Assignee:	Amersham Health AS (Oslo, NO)
Application Number:	09/506,682
Patent Claims:	1. In a process for the preparation of a pharmaceutical composition comprising an aqueous dispersion of gas-containing vesicles having membranes comprising amphiphilic membrane-forming material, said material including at least one phospholipid having an overall negative charge, said process comprising: (i) generating an aqueous dispersion of gas-containing vesicles from a mixture comprising said amphiphilic membrane-forming material; and (ii) lyophilizing said aqueous dispersion of gas-containing vesicles; and (iii) reconstituting the lyophilized product of step (ii) with a sterile aqueous liquid to produce an aqueous dispersion of gas-containing vesicles, the improvement comprising effecting said reconstitution in step (iii) with a sterile aqueous liquid such that the ratio of the total molar concentration in the aqueous dispersion of non-chelated Al, Ba, Mg, Ca and Zn ions to the molar concentration of said negatively charged phospholipid is less than 1:3. 2. The process of claim 1 wherein said ratio of the total molar concentration in the aqueous dispersion of non-chelated Al, Ba, Mg, Ca and Zn ions to the molar concentration of negatively charged phospholipid is less than 1:6. 3. The process of claim 1 wherein the total molar concentration in the aqueous dispersion of non-chelated Al, Ba, Ca, Mg, and Zn ions is less than 47 .mu.M. 4. The process of claim 1 wherein said amphiphilic membrane-forming material includes at least one phosphatidylserine. 5. The process of claim 1 wherein the aqueous dispersion produced in step (i) is treated prior to step (ii) to increase the amount or the surface area of said amphiphilic membrane-forming material. 6. The process of claim 1 wherein the aqueous dispersion produced in step (i) is fractionated by flotation, filled into vials and then immediately frozen for lyophilisation in accordance with step (ii). 7. The process of claim 1 wherein the aqueous dispersion produced in step (i) is filtered and/or subjected to mechanical stress prior to step (ii). 8. The process of claim 1 wherein the reconstituted aqueous dispersion produced in step (iii) is filtered and/or subjected to mechanical stress prior to use. 9. The process of claim 1 wherein the sterile aqueous liquid employed in step (iii) is sterile water. 10. The process of claim 1 wherein the sterile aqueous liquid employed in step (iii) is sterile water containing one or more solutes selected from the group consisting of chelating agents, osmolality adjusting agents and pH regulators.

Details for Patent 6,509,004

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2017-08-19